Role of novel KCND3 variants in human peripheral pain processing
- Project duration: May 2021 - May 2023
- Project status: Approval by the Scientific Committee
- Funding: Provincial P.-L.P. 14. Mobility (Province BZ funding /Project)
In Europe one in five people is affected by chronic pain, causing a large socio-economic burden, with costs running in the billions. Almost half (40%) of chronic pain patients feels their pain management is inadequate, and there is a desperate need to develop new analgesic drugs. Pain is a complex trait influenced by many genetic factors. New large genome wide association studies (GWAS) have identified a number of genes associated with pain in humans. For many, their functional significance remains to be ascertained. Within one of the largest single site longitudinal cohorts with large pedigrees, familial history and genotypes in Europe (the CHRIS study), the Institute for Biomedicine has identified KCND3 to be associated with pain phenotypes. Through exome-sequencing the institute has recently identified 90 carriers of 9 missense and 1 frame-shift variants predicted to be damaging. Many of the carriers of these variants manifest moderate to severe chronic pain phenotypes.
The protein encoded by KCND3 is responsible for subthreshold A-type K+ currents in sensory neurons, which can inhibit neuronal excitability below the threshold of action potential (AP). In rodent sensory neurons, KCND3 expression is enriched within the C-fiber low-threshold mechanoreceptors (C-LTMRs) population of cutaneous afferents, responsible for the detection of pleasant touch. Both KCND3 and C-LTMRs have been implicated in pre-clinical models of chronic pain. This has led us to the hypothesis, that the novel KCND3 variants are loss-of-function mutations, resulting in increased excitability of C-LTMRs, leading to abnormal pain. Through this project “ISAP” we will provide novel insights into the functional significance of KCND3 in human peripheral pain processing and generate a platform for future testing of potential analgesic drugs targeting this potassium channel.
Epigenetics of Immunity in CancerDuration: September 2019 - October 2021Funding:
CHRIS-2D: a Dynamic Data infrastructure for biomedical research and innovation in South TyrolDuration: June 2020 - October 2021Funding:
Innovative therapies for cardiovascular disease.Duration: October 2020 - October 2021Funding:
Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discoveryDuration: December 2019 - October 2021Funding: